

SUPPLEMENTARY DATA

Supplementary Table 1. Patient Baseline Characteristics.

Characteristic	Statistic	Placebo	0.6 mg LY	18 mg LY	180 mg LY
Age (years)	Mean (SD)	52.9 (9.4)	52.9 (6.8)	53.7 (10.7)	51.3 (9.2)
	n	27	26	26	27
Baseline BMI (kg/m ²)	Mean (SD)	32.5 (4.6)	33.0 (3.7)	33.7 (3.7)	33.1 (4.0)
	n	27	26	26	27
Baseline CrCl (mL/min)	Mean (SD)	82.3 (23.5)	88.9 (23.1)	80.9 (26.9)	91.7 (25.1)
	n	25	20	21	23
Diabetes Duration (years)	Mean (SD)	8.0 (6.8)	5.0 (4.5)	7.6 (4.6)	8.2 (7.7)
	n	25	19	21	23
Gender	n	27	26	26	27
Female	n (%)	20 (74.1)	15 (57.7)	17 (65.4)	15 (55.6)
Male	n (%)	7 (25.9)	11 (42.3)	9 (34.6)	12 (44.4)
hsCRP (mg/L)	Mean (SD)	6.1 (4.4)	5.9 (4.8)	7.1 (5.0)	8.3 (7.3)
	n	25	20	21	23
HDL (mmol/L)	Mean (SD)	1.3 (0.3)	1.2 (0.3)	1.3 (0.3)	1.2 (0.3)
	n	25	20	19	22
LDL (mmol/L)	Mean (SD)	3.0 (1.2)	2.6 (0.7)	2.9 (1.1)	2.8 (1.1)
	n	25	19	18	21
TG (mmol/L)	Mean (SD)	1.9 (0.7)	2.2 (1.6)	3.1 (4.7)	2.0 (1.03)
	n	25	20	21	23
Glucose (mmol/L)	Mean (SD)	9.7 (2.2)	8.1 (1.8)	9.2 (2.3)	10.7 (2.7)
	n	25	20	21	23
Insulin (□IU/mL)	Mean (SD)	14.9 (12.1)	15.3 (10.6)	13.9 (6.6)	15.5 (14.2)
	n	25	20	21	23
HbA _{1c} (%)	Mean (SD)	7.9 (0.7)	7.6 (0.6)	8.1 (0.8)	8.4 (1.0)
	n	25	20	21	23
Subjects included in anti-diabetic therapy analysis	n	27	26	26	27
Diet and Exercise Alone	n (%)	7 (25.9)	5 (19.2)	3 (11.5)	4 (14.8)
Biguanides	n (%)	20 (74.1)	20 (76.9)	23 (88.5)	22 (81.5)
GLP analogs & antagonists	n (%)	0 (0)	1 (3.8)	0 (0)	0 (0)
DPP-4 Inhibitors	n (%)	0 (0)	0 (0)	0 (0)	4 (14.8)

SUPPLEMENTARY DATA

Sulfonylureas	n (%)	6 (22.2)	8 (30.8)	7 (26.9)	5 (18.5)
Enhancers of Insulin Effect	n (%)	0 (0)	0 (0)	1 (3.8)	0 (0)

SD=Standard Deviation; CrCl = creatinine clearance; GLP=Glucagon-like peptide; DPP-4=dipeptidyl peptidase 4; HbA_{1c}= hemoglobin A1c; TG=triglycerides; hsCRP=high-sensitivity C-reactive protein; HDL= High-density lipoprotein (cholesterol); LDL=low density lipoprotein (cholesterol); LY= LY2189102.


Supplementary Table 2. HbA_{1c} mean change from baseline over time by treatment.

LY treatment (mg)		Week				
		6	10	12	18	24
0.6	LS Mean Difference	-0.27	-0.27	-0.27	-0.31	-0.18
	95% CI	(-0.58, 0.05)	(-0.59, 0.05)	(-0.61, 0.08)	(-0.80, 0.18)	(-0.76, 0.41)
18	LS Mean Difference	-0.29	-0.37	-0.396	-0.48	-0.59
	95% CI	(-0.64, 0.06)	(-0.74, 0.00)	(-0.79, 0.00)	(-1.04, 0.08)	(-1.25, 0.07)
180	LS Mean Difference	-0.20	-0.23	-0.22	-0.39	-0.43
	95% CI	(-0.54, 0.13)	(-0.59, 0.13)	(-0.59, 0.15)	(-0.93, 0.15)	(-1.07, 0.21)

LS Mean differences (LY minus placebo change from baseline) based on ANCOVA, with treatment, site, and baseline HbA_{1c} (%) as covariates. Analyses were performed using the compliant set. Baseline was the mean of Weeks -2 and 0 (or a single value if one was missing). End-of-dosing was the mean of Weeks 10 and 12 (or a single value if one was missing).

SUPPLEMENTARY DATA

Supplementary Figure 1. Study design.



SUPPLEMENTARY DATA

Supplementary Figure 2. Patient disposition from randomization through study completion. Week 13 indicates the timing of sample collection for pharmacodynamic measurements after last dose of study drug.

